{"id":"https://openalex.org/W2030677705","doi":"https://doi.org/10.1017/s1461145704004109","title":"Amisulpride \u2013 a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials","display_name":"Amisulpride \u2013 a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials","alternate_titles":[],"publication_year":2004,"publication_date":"2004-02-19","ids":{"openalex":"https://openalex.org/W2030677705","doi":"https://doi.org/10.1017/s1461145704004109","mag":"2030677705","pmid":"https://pubmed.ncbi.nlm.nih.gov/14972080"},"language":"en","primary_location":{"id":"doi:10.1017/s1461145704004109","doi":"https://doi.org/10.1017/s1461145704004109","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s1461145704004109","pdf_url":"https://academic.oup.com/ijnp/article-pdf/7/Supplement_1/S15/3021895/7-Supplement_1-S15.pdf","source":{"id":"https://openalex.org/S199972112","display_name":"The International Journal of Neuropsychopharmacology","issn_l":"1461-1457","issn":["1461-1457","1469-5111"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311647","host_organization_name":"University of Oxford","host_organization_lineage":["https://openalex.org/P4310311647"],"host_organization_lineage_names":["University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The International Journal of Neuropsychopharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2030677705"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://academic.oup.com/ijnp/article-pdf/7/Supplement_1/S15/3021895/7-Supplement_1-S15.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002251483","display_name":"Stefan Leucht","orcid":"https://orcid.org/0000-0002-4934-4352","observed_orcids":["https://orcid.org/0000-0002-4934-4352"]},"institutions":[{"id":"https://openalex.org/I4210147185","display_name":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie","ror":"https://ror.org/03j546b66","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I3018771216","https://openalex.org/I4210147185","https://openalex.org/I8204097"]},{"id":"https://openalex.org/I62916508","display_name":"Technical University of Munich","ror":"https://ror.org/02kkvpp62","country_code":"DE","type":"education","lineage":["https://openalex.org/I62916508"]}],"countries":["DE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Stefan Leucht","raw_affiliation_strings":["Klinik fr Psychiatrie und Psychotherapie der Technischen Universitt, Ismaningerstr. 22, 81675, Muenchen, Germany. stefan.leucht@lrz.tu-muenchen.de","Klinik f\u00fcr Psychiatrie und Psychotherapie der Technischen Universit\u00e4t, Ismaningerstr. 22, 81675, Muenchen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Klinik fr Psychiatrie und Psychotherapie der Technischen Universitt, Ismaningerstr. 22, 81675, Muenchen, Germany. stefan.leucht@lrz.tu-muenchen.de","institution_ids":["https://openalex.org/I62916508"]},{"raw_affiliation_string":"Klinik f\u00fcr Psychiatrie und Psychotherapie der Technischen Universit\u00e4t, Ismaningerstr. 22, 81675, Muenchen, Germany","institution_ids":["https://openalex.org/I4210147185","https://openalex.org/I62916508"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5002251483"],"corresponding_institution_ids":["https://openalex.org/I4210147185","https://openalex.org/I62916508"],"apc_list":{"value":2042,"currency":"GBP","value_usd":2693},"apc_paid":null,"fwci":0.6339,"has_fulltext":true,"cited_by_count":67,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.53114754,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"7","issue":"5","first_page":"S15","last_page":"S20"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/amisulpride","display_name":"amisulpride","score":1.0},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.9919999837875366},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.6919999718666077},{"id":"https://openalex.org/keywords/negative-symptoms","display_name":"negative symptoms","score":0.9589999914169312},{"id":"https://openalex.org/keywords/extrapyramidal-symptoms","display_name":"extrapyramidal symptoms","score":0.8980000019073486},{"id":"https://openalex.org/keywords/conventional-neuroleptics","display_name":"conventional neuroleptics","score":0.9039999842643738},{"id":"https://openalex.org/keywords/clozapine","display_name":"clozapine","score":0.7379999756813049},{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":0.996999979019165},{"id":"https://openalex.org/keywords/quetiapine","display_name":"quetiapine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/risperidone","display_name":"risperidone","score":0.9990000128746033},{"id":"https://openalex.org/keywords/mesolimbic-dopamine-system","display_name":"mesolimbic dopamine system","score":0.6510000228881836},{"id":"https://openalex.org/keywords/antipsychotic-efficacy-and-safety","display_name":"antipsychotic efficacy and safety","score":0.7229999899864197}],"concepts":[{"id":"https://openalex.org/C2778999636","wikidata":"https://www.wikidata.org/wiki/Q418785","display_name":"Amisulpride","level":4,"score":0.9901462197303772},{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.7107369303703308},{"id":"https://openalex.org/C2780864610","wikidata":"https://www.wikidata.org/wiki/Q221361","display_name":"Clozapine","level":3,"score":0.702614963054657},{"id":"https://openalex.org/C2780616385","wikidata":"https://www.wikidata.org/wiki/Q1385411","display_name":"Extrapyramidal symptoms","level":4,"score":0.6306557655334473},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.6150544285774231},{"id":"https://openalex.org/C2780634440","wikidata":"https://www.wikidata.org/wiki/Q408535","display_name":"Quetiapine","level":3,"score":0.6072538495063782},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.5379228591918945},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.5210973024368286},{"id":"https://openalex.org/C44208683","wikidata":"https://www.wikidata.org/wiki/Q15335165","display_name":"Dopamine receptor D2","level":3,"score":0.45175424218177795},{"id":"https://openalex.org/C2778528637","wikidata":"https://www.wikidata.org/wiki/Q4967025","display_name":"Brief Psychiatric Rating Scale","level":3,"score":0.4295109212398529},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4140589237213135},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4026937484741211},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3083769679069519},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.3049567937850952},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.29440194368362427},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2856810986995697},{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.24141672253608704}],"mesh":[{"descriptor_ui":"D000077582","descriptor_name":"Amisulpride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008032","descriptor_name":"Limbic System","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D008636","descriptor_name":"Mesencephalon","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D010054","descriptor_name":"Brief Psychiatric Rating Scale","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012565","descriptor_name":"Schizophrenic Psychology","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D013469","descriptor_name":"Sulpiride","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013469","descriptor_name":"Sulpiride","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D013469","descriptor_name":"Sulpiride","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018492","descriptor_name":"Dopamine Antagonists","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018492","descriptor_name":"Dopamine Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D050637","descriptor_name":"Receptors, Dopamine D3","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065127","descriptor_name":"Dopamine D2 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1017/s1461145704004109","doi":"https://doi.org/10.1017/s1461145704004109","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s1461145704004109","pdf_url":"https://academic.oup.com/ijnp/article-pdf/7/Supplement_1/S15/3021895/7-Supplement_1-S15.pdf","source":{"id":"https://openalex.org/S199972112","display_name":"The International Journal of Neuropsychopharmacology","issn_l":"1461-1457","issn":["1461-1457","1469-5111"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311647","host_organization_name":"University of Oxford","host_organization_lineage":["https://openalex.org/P4310311647"],"host_organization_lineage_names":["University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The International Journal of Neuropsychopharmacology","raw_type":"journal-article"},{"id":"pmid:14972080","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14972080","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The international journal of neuropsychopharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:mediatum.ub.tum.de:node/1333910","doi":null,"is_oa":false,"landing_page_url":"https://mediatum.ub.tum.de/1333910","pdf_url":null,"source":{"id":"https://openalex.org/S4306400453","display_name":"mediaTUM (Technical University of Munich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I62916508","host_organization_name":"Technical University of Munich","host_organization_lineage":["https://openalex.org/I62916508"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1017/s1461145704004109","doi":"https://doi.org/10.1017/s1461145704004109","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s1461145704004109","pdf_url":"https://academic.oup.com/ijnp/article-pdf/7/Supplement_1/S15/3021895/7-Supplement_1-S15.pdf","source":{"id":"https://openalex.org/S199972112","display_name":"The International Journal of Neuropsychopharmacology","issn_l":"1461-1457","issn":["1461-1457","1469-5111"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311647","host_organization_name":"University of Oxford","host_organization_lineage":["https://openalex.org/P4310311647"],"host_organization_lineage_names":["University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The International Journal of Neuropsychopharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2030677705.pdf","grobid_xml":"https://content.openalex.org/works/W2030677705.grobid-xml"},"referenced_works_count":15,"referenced_works":["https://openalex.org/W45776812","https://openalex.org/W1981210131","https://openalex.org/W2005025328","https://openalex.org/W2035155339","https://openalex.org/W2047458453","https://openalex.org/W2083915390","https://openalex.org/W2086179447","https://openalex.org/W2097126175","https://openalex.org/W2110339794","https://openalex.org/W2111105929","https://openalex.org/W2115125760","https://openalex.org/W2129827461","https://openalex.org/W2155847604","https://openalex.org/W2402363043","https://openalex.org/W2411826586"],"related_works":["https://openalex.org/W2115125760","https://openalex.org/W2401224391","https://openalex.org/W4229570842","https://openalex.org/W2483947977","https://openalex.org/W2055602194","https://openalex.org/W2067816980","https://openalex.org/W2130415481","https://openalex.org/W2092636839","https://openalex.org/W1991440969","https://openalex.org/W2009710166"],"abstract_inverted_index":{"The":[0,71],"pharmacological":[1],"profiles":[2],"of":[3,54,66,91,99,102,118,168],"the":[4,38,62,79,86,89,125,206,213,217],"atypical":[5,127],"antipsychotics,":[6],"clozapine,":[7],"olanzapine,":[8],"quetiapine":[9],"and":[10,18,64,180,200,223],"risperidone,":[11],"all":[12],"show":[13,193],"a":[14,25,48,96,160,164],"combined":[15,209],"serotonin":[16],"(5-HT2)":[17],"dopamine":[19,28],"type-2":[20],"(D2)":[21],"receptor":[22,30],"antagonism.":[23],"Amisulpride,":[24],"highly":[26],"selective":[27],"D2/D3":[29],"antagonist":[31],"that":[32,194,208],"binds":[33],"preferentially":[34],"to":[35,60,116,123,151,184],"receptors":[36],"in":[37,73,166,170],"mesolimbic":[39],"system,":[40],"is":[41,196,212],"also":[42],"an":[43,197],"'atypical'":[44,198],"antipsychotic":[45,128],"despite":[46],"having":[47],"different":[49],"receptor-affinity":[50],"profile.":[51],"A":[52],"meta-analysis":[53],"18":[55],"clinical":[56],"trials":[57],"was":[58,76,107,148,174],"undertaken":[59],"compare":[61],"efficacy":[63,219],"safety":[65],"amisulpride":[67,106,147,169,195],"with":[68,114,156,176],"conventional":[69,112,157,188],"antipsychotics.":[70],"improvement":[72,117],"mental":[74],"state":[75],"assessed":[77],"using":[78],"Brief":[80],"Psychiatric":[81],"Rating":[82],"Scale":[83,87],"(BPRS)":[84],"or":[85],"for":[88,129,216],"Assessment":[90],"Negative":[92],"Symptoms":[93],"(SANS).":[94],"In":[95,143],"pooled":[97],"analysis":[98],"10":[100],"studies":[101,132,155],"acutely":[103],"ill":[104],"patients,":[105],"significantly":[108,149],"more":[109],"effective":[110],"than":[111,187],"neuroleptics":[113,158],"regard":[115],"global":[119],"symptoms.":[120],"Amisulpride":[121,173],"is,":[122],"date,":[124],"only":[126,163,214],"which":[130],"several":[131],"on":[133,205],"patients":[134],"suffering":[135],"predominantly":[136],"from":[137],"negative":[138,221],"symptoms":[139,222],"have":[140],"been":[141],"published.":[142],"four":[144],"such":[145],"studies,":[146],"superior":[150],"placebo.":[152],"Three":[153],"small":[154],"as":[159],"comparator":[161],"showed":[162],"trend":[165],"favour":[167],"this":[171],"regard.":[172],"associated":[175],"fewer":[177,181,224],"extrapyramidal":[178,225],"side-effects":[179],"drop-outs":[182],"due":[183],"adverse":[185],"events":[186],"neuroleptics.":[189],"These":[190],"results":[191],"clearly":[192],"antipsychotic,":[199],"they":[201],"cast":[202],"some":[203],"doubt":[204],"notion":[207],"5-HT2-D2":[210],"antagonism":[211],"reason":[215],"high":[218],"against":[220],"side-effects.":[226]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2030677705","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-22T12:46:00.618207","created_date":"2016-06-24T00:00:00"}
